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Objectives
• Discuss common pump
errors
• Review titratable drips
–
–
–
–
–

Mechanism of Action (MOA)
Indication
Starting and max rates
Adverse effects
Monitoring

• Focus on heparin protocol
• Practice a calculation
• Apply to a patient case

Titratable Drips Discussed
–
–
–
–
–
–
–
–
–

Vasopressors
Inotropes
Insulin
Analgesics: opioids
Sedatives
Neuromuscular blockers
Antiarrhythmics
Antithrombotics
Antihypertensives
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General Information
• Definition of titration
• Check vital signs every 15 min when
actively titrating
• No IV drips may be run as an IVPB
• Choose CCA: ICU/IMC-card (or ICU-gen)

3

Common Pump Errors
• Choosing the
wrong drug/conc.
from the library
(verify drip conc.
matches pump
conc.)

• Entering the
wrong pt weight
• Choosing “Drug
not in Library”
and entering the
wrong
concentration
from the label
4
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VASOPRESSORS
Norepinephrine
Epinephrine
Vasopressin
Dopamine
Phenylephrine
5

General Guidelines for Pressors
• Treat hypovolemia induced hypotension with
fluids PRIOR TO giving vasopressors
• Titrate one pressor at a time
• Central line
– Monitor infusion site for extravasation
– Antidote: phentolamine (an alpha-receptor antagonist)
intradermally

• DO NOT administer sodium bicarbonate in the
same line as any vasopressor (incompatible).
6
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Common Adverse Effects of Pressors
• Hypoperfusion (skin, kidneys, GI tract, etc),
dysrhythmias, myocardial ischemia
• Warning: high doses can result in peripheral and
mesenteric ischemia leading to digit loss and bowel
necrosis
• If you are close to the max rate, it is time to add another
pressor. Do NOT continue to increase the rate.

7

Receptors
Receptor

Site

Action

Alpha-1 (α1)

Smooth muscle (vascular,
sphincters)

Smooth muscle contraction,
vasoconstriction

Alpha-2 (α2)

CNS

Inhibits norepinephrine
release
↓HR, ↓BP

Beta-1 (ß1)

Heart

↑contractility (inotrope), ↑ HR
(chronotrope), ↑automaticity,
↑ conduction velocity

Beta-2 (ß2)

Smooth muscle (vascular,
bronchioles, intestine)

Vasodilation

Dopaminergic (D)

Vascular smooth muscle (renal,
mesenteric, coronary)

Vasodilation

Vasopressin (V1, V2)

Kidney

↑ free water retention, ↑
SVR, vasoconstriction

8
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Vasopressors
Drug

Dose Range

Receptor

Effect

Dopamine (Intropin®)

1-5 mcg/kg/min
5-10 mcg/kg/min
10-20 mcg/kg/min

D>ß2> ß1
ß1, ß2>D> α1
α1> ß1, ß2>>D

Increase HR,
contractility, and SVR

Epinephrine
(Adrenalin®)

0.01-0.04 mcg/kg/min
0.05-1 mcg/kg/min

ß1, ß2 >> α1
ß1 > α1, ß2

↑↑HR, ↑contractility,
↓SVR↑ HR,
↑contractility, ↑SVR

Norepinephrine
(Levophed®)

0.5-30 mcg/min
0.01-1 mcg/kg/min

α1> ß1
α1>> ß1

↑SVR, ↑contractility, ↓
HR,↑↑SVR

Phenylephrine
(Neosynephrine®)

40-180 mcg/min

α1

↑↑SVR

Vasopressin
(Pitressin®)

0.01-0.04 units/min
2-4 units/hour

V1, V2

↑↑SVRwater resorption
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NorEPINEPHrine (Levophed®)
• Potent alpha-1 agonist activity, weak beta-1 activity
(may see ↑ HR)
• First line vasopressor for septic shock (after fluids).
Can also be used for other types of shock.
• WATCH for decreased cardiac output, reflex
bradycardia, and chest pain or ventricular arrhythmias
Concentration

4 mg/250 mL (DS 8 mg/250 mL, QS 16 mg/250 mL)
May be mixed in the ICU in an emergency

Starting Dose

0.01 mcg/kg/min (or 8 mcg/min)

Titration

Increase by 0.05 mcg/kg/min every 1 minute to
maintain SBP greater than 90 mmHg (or as
ordered)

Maximum Rate 3 mcg/kg/min (or 30 mcg/min)

10
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Vasopressin (Pitressin®)
• Other name: antidiuretic hormone (ADH)
• MOA: stimulates vasopressin receptor  vasoconstriction
and free water retention (no inotropic or chronotropic
effects)
• Indication:
– Second agent to add in septic shock (add to norepinephrine)
– Post-CABG
– Not a stand-alone agent

• Watch for arrhythmia, asystole, or ↓ CO
Concentration

100 units/100 mL

Usual rate

2-4 units/hour

Titration

Fixed rate (not titrated).

Maximum Rate

6 units/hour
11

EPINEPHrine (Adrenalin®)
• Has almost equal alpha-1, beta-1, and beta-2 agonist
activity (↑ HR, CO, SV, and SVR)
• Indication:
– Septic shock: preferred agent to add to norepi + vasopressin
– Bradycardia, anaphylactic shock, cardiac arrest, post-CABG

• WATCH for HTN, dysrhythmias, tachycardia,
hyperglycemia
Concentration

1 mg/250 mL (DS 2 mg/250 mL, QS 4 mg/250 mL)
May be mixed in the ICU in an emergency

Starting Dose

0.01 mcg/kg/min

Titration

Increase by 0.05 mcg/kg/min every 1 minute to
maintain SBP greater than 90 mmHg (or as
ordered)

Maximum Rate

0.6 mcg/kg/min

12
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Dopamine
• Indication:
– Hypotension or symptomatic bradycardia
– No longer recommended in septic shock

• DO NOT USE in patients with
– Uncorrected tachyarrhythmias
– Ventricular fibrillation
Concentration

Premix 800 mg/500 mL (DS 800 mg/250 mL)

Starting Dose

5 mcg/kg/min

Titration

Increase by 1-4 mcg/kg/min every 10 minutes
Dose dependent effects:
5-10 mcg/kg/min (cardiac dosing/β1 receptors): increased renal blood flow, HR,
cardiac contractility, cardiac output
>10 mcg/kg/min (vasopressor dosing/α1 receptors) : vasoconstriction, increased
blood pressure, HR

Maximum Rate

20 mcg/kg/min (greater doses may not improve BP but may increase arrhythmias)
13

Dopamine
– No “renal dose” of dopamine
• Low doses will increase UOP but do NOT improve or
protect renal function

– Adverse effects
• Common vasopressor ADRs, but especially tachycardia,
tachyarrhythmias, and angina
• These hamper clinical use and are more common with
higher doses.
• Studies have shown an increased mortality due to
tachyarrhythmias in septic shock, and this is why
dopamine is no longer recommended in septic shock (only
to be used as a salvage drug).
14
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PHENYLephrine (Neosynephrine®)
• Acts as a pure alpha-1 agonist ONLY
•

Indication:
– Hypotension in patients with tachyarrhythmias (afib) since no B1 effects
– Not recommended in septic shock Use as a second or third-line therapy to
treat hypotension from shock resistant to other vasopressor agents (salvage
therapy).

• Use extreme caution in HF or cardiogenic shock; ↑ SVR may
significantly ↓ CO
•

WATCH for ↓ CO, reflex bradycardia, severe peripheral and visceral
vasoconstriction

Concentration

60 mg/100 mL

Starting Dose
Titration

100-180 mcg/min until BP stabilized
Increase by 10 mcg/min every 1 minute to maintain SBP >
90. Once BP stabilized, decrease to 40-60 mcg/min

Maximum Rate

180 mcg/min
15

Vasopressors
B1

Epinephrine
Dopamine
Norepinephrine
Phenylephrine

a1
16
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Application
• LT is a 78 year old man who presents to ER with
AMS, SOB, cough with yellow sputum, and fever
from a nursing home. He is diagnosed with
sepsis secondary to HCAP.
• PMH: COPD, DM2, HTN
• VS: P 102 BP 78/34
RR 30 T 38.4 °C
• What is the first intervention you would recommend for
the BP?
• After the intervention, BP is 83/42. What is your next
recommendation?
• BP is 88/44. What now?
17

INOTROPES
Recall that ionotropic refers to increased strength of
contraction of heart muscle  increased cardiac
output and stroke volume.

18
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Dobutamine (Dobutrex®)
•
•
•

•

Potent beta-1 agonist: strong positive ionotropic activity
Some beta-2 and alpha agonist activity. Because of B-2 activity, dobutamine
does not cause vasoconstriction and may ↓ BP
Indications
– Septic shock: pts with low CO and high filling pressures (CI < 3 L/min/m 2
or ScVO2 < 70%)
– Cardiogenic shock. Vasopressors may need to be given to counteract
arterial vasodilation.
WATCH for: hypotension, hypertension, arrhythmias
Concentration

Premix 250 mg/250 mL
(DS 500 mg/250 mL, QS 1000 mg/250 mL)

Starting dose

5 mcg/kg/min

Titration

Gradually adjust rate at 2-10 minute intervals
according to Cardiac Index (CI) goal

Max Rate

20 mcg/kg/min (40 mcg/kg/min)

19

Milrinone (Primacor®)
•

MOA: inotrope (phosphodiesterase-3 inhibitor)
– Dose-dependent VD can ↑ CO through SVR reduction
– Lowering of PAP  beneficial in patients with pulmonary congestion due to LV
dysfunction (pulmonary hypertension).

•
•
•
•

Indication: acute decompensated heart failure, post-CABG, ↑ PAP
Typical 1-3 hour delay in hemodynamic effects
Rate requires adjustment for renal impairment
WATCH for: arrhythmias, hypotension (esp. with LD), hepatotoxicity

Concentration

Premix 40 mg/200 mL

Maintenance dose

0.375-0.75 mcg/kg/min
50 mcg/kg loading dose over 10 min optional,
hypotension likely

Titration

Titrate by 0.2 mcg/kg/min every 30 minutes to goal CI

Max Rate

0.75 mcg/kg/min

20
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Application
• LT’s BP is being maintained on two
pressors. However, his ScVO2 is 65%.
You check his hemoglobin and it is 9 g/dL.
• What is your recommendation to improve his
ScVO2?

21

INSULIN

22
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Insulin Regular
•
•

Regular ONLY
Indications:
– DKA / HHNK
– Post-op hearts
– High doses of epinephrine infusions

•
•
•

Flush with 20 mL to minimize adsorption to IV tubing
Monitoring: goal BG 100-159. Check FSBS initially every hour
Powerplans:
–
–
–

Protocol Hyperglycemia Management (XY)
Protocol Intensive Insulin Infusion
ENDO DKA PowerPlan

Concentration

100 units/100 mL

Starting rate

1-10 units/hour, depending on protocol severity
ordered

Titration

Per protocol

Max rate

Per protocol. Notify provider if rate > 40 units/hr

23

Application
• LT’s blood glucose ranges from 190-280
mg/dL.
• What recommendation would you make to
the physician?
• What medication is LT receiving that could
affect his blood glucose?

24
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ANALGESICS
Fentanyl
Morphine
Hydromorphone

25

Analgesia
Physical Effects of Pain
Muscle breakdown,
Respiratory Effects poor wound healing
- Shallow breathing
- Tachypnea

Stress
Response
- Tachycardia
- Hypertension
- ↑ myocardial O2
consumption

Pain
Increased risk
for DVT/PE

Agitation

Immunosuppression

26
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Underlying Medical
Conditions
(chronic pain, arthritis,
substance abuse
history, psychiatric
illness)

Monitoring and
Therapeutic
Devices
(catheters, drains,
mechanical
ventilation)

ICU
Environmental
Influences
(lights, noises)

Routine Nursing
Care

Acute
Illness

(airway suctioning,
physical therapy,
dressing changes)

Anxiety, Pain, Delirium
Management of
predisposing & causative
conditions

Interventions

Dangerous
Agitation

Calm/alert
No pain, anxiety

Agitation

Pain, Anxiety

Sedative, analgesic,
antipsychotic medications

Lightly
Sedated

Deeply
Sedated

Unresponsive

Pain
• Assess pain regularly
• Treatment
– Nonpharmacological
• Positioning of patient
• Positioning of ventilator and feeding tubes
• Heat or cold therapy

– Pharmacological
• Opioids (most common in ICU)
• Non-opioid: APAP, NSAIDs

28
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Opioid Analgesics
• Fentanyl
– Most rapid onset, shortest
duration
• Preferred in acutely
distressed pts
• Preferred in short procedures
– Accumulation and prolonged
effects in repeated dosing

• Morphine
– Longer duration, intermittent
doses may be given
– Active metabolite: prolonged in
renal insufficiency
– Histamine release
– Hypotension may result

• Hydromorphone
– Duration similar to morphine
– Lacks active metabolite or
histamine release
– Confused with morphine but is
~7 times stronger than morphine!

• Meperidine
• Avoid due to potential for
neurotoxicity
• Normeperidine causes
neuroexcitation (apprehension,
tremors, delirium, seizures)
• Interact with antidepressants (can
cause serotonin syndrome)
29

Analgesic Administration
• Preventing pain is more effective than treating established
pain
• Administer on a scheduled or scheduled intermittent basis
+ PRN doses
• Patient Controlled Analgesia (PCA)
• Continuous Infusion- done through the PCA pumps at ISMC
• PRN only not as effective
• Monitor for respiratory depression, constipation (schedule
stool softeners and/or laxatives as needed), hypotension

30
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SEDATIVES
Propofol
Midazolam
Lorazepam
Dexmedetomidine
31

Sedative Selection
• Sedate agitated patients only after adequate
analgesia and treatment of reversible causes
• 2002 SCCM Sedation Guidelines
– Midazolam only for short-term sedation (< 2 days)
– Lorazepam for long-term sedation (> 3 days)
– Propofol for patients requiring intermittent awakenings

• 2013 version non-benzodiazepine sedatives
(propofol, dexmedetomidine) may be preferred to
improve outcomes

32
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Sedation Scale
Richmond Agitation Sedation Scale (RASS)
+4

Combative

+3

Very agitated

+2

Agitated

+1

Restless

0

Alert and calm

-1

Drowsy

-2

Light sedation

-3

Moderate sedation

-4

Deep sedation

-5

Unarousable
33

Propofol (Diprivan®)
• MOA: general anesthetic for sedation
• Shortest acting sedative (duration 10-15 min;
accumulates over time
• Contraindications: egg allergy, no MV
• Administration
– Vented tubing
– Dedicated line (potential incompatibility and infection)
– Strict aseptic technique must be used due to a high infection
risk. Tubing and vial MUST be changed every 12 hours

• Green urine is rare but may
occur due to phenolic metabolites
34
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Propofol (Diprivan®)
• WATCH for:
– Hypotension (especially after bolus dosing)
– Bradycardia
– Respiratory depression or apnea
– Pancreatitis- monitor triglycerides
– Propofol-related infusion syndrome (PRIS)
• Risk increases with increasing dose and duration
• Syndrome of lactic acidosis, bradycardia, hyperlipidemia, and
rhabdomyolysis
• Incidence 1 %, mortality 33%

35

Propofol (Diprivan®)
Usual
Concentration

1000 mg/100 mL premixed and undiluted

Bolus Dose

NURSING CANNOT BOLUS DOSE

Starting Dose

5 mcg/kg/min

Titration

May increase by 5-10 mcg/kg/min every 5 minutes until at
target sedation

Weaning

Decrease by 5-10 mcg/kg/min every 5 minutes. Abrupt
discontinuation associated with anxiety, agitation, and
resistance to mechanical ventilation.

Maximum
Infusion Rate

50 mcg/kg/min (physician’s order required for higher rates)

36

18

Y-site Compatibility with Propofol
Drug

Y-site Compatible?

Amiodarone (Cordarone®)
Diltiazem (Cardizem®)
Dobutamine (Dobutrex®)
Dopamine
Epinephrine (Adrenalin®)
Eptifibatide (Integrilin®)
Esmolol (Brevibloc®)
Fentanyl
Heparin
Labetalol
Lorazepam
Midazolam (Versed®)
Morphine
Nicardipine (Cardene®)
Nitroglycerin
Nitroprusside (Nipride®)
Norepinephrine (Levophed®)
Phenylephrine (Neosynephrine®)
Vasopressin (Pitressin®)

NO
NO
Yes
Yes
Yes
NO
Yes
NO
Yes
Yes
NO
NO
Yes
NO
Yes
NO
Yes
NO
NO
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Benzodiazepines
Midazolam (Versed)
Lorazepam (Ativan)

•
•
•

MOA: binds to benzodiazepine receptors
Indication: sedation
Factors affecting intensity and duration of effect
– Delayed emergence from sedation with prolonged administration (due to
saturation of tissues) in elderly patients, hepatic dysfunction (all BZDs are
metabolized by the liver), or renal insufficiency
– Prior alcohol abuse and concurrent drug therapy may increase the dosages
required

•

Adverse effects
– Respiratory depression and hypotension, especially when given with opioids
– May also contribute to delirium
– Potential for accumulation

•

Reversal: flumazenil (Romazicon®) not recommended
– Risk of inducing withdrawal after prolonged therapy
– Reversal of patients on BZD for seizures or increased intracranial pressure could
precipitate these events
38
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Midazolam (Versed®)
• Used most often for procedures requiring moderate
sedation as IVP
• Rapid onset, short duration of action with single doses
(useful for acute agitation)
• Accumulation and prolonged sedation due to active
metabolite, especially in renal insufficiency

Concentration

100 mg/100 mL

Starting rate

1 mg/hr

Titration

Titrate by 2 mg/hr every 10 minutes to goal RASS

Max rate

10 mg/hr
39

Lorazepam (Ativan®)
• Slightly slower onset than midazolam, less useful for acute
agitation
• Infusion is not readily titratable due to half life of ~8 hours
• Commonly used to treat alcohol withdrawal and seizures
• Solvent is propylene glycol. May cause reversible acute
tubular necrosis, lactic acidosis, and hyperosmolar states
Concentration

40 mg/50 mL

Starting rate

1 mg/hr

Titration

Titrate by 2 mg/hr every 10 minutes to goal RASS

Max rate

10 mg/hr
40
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Dexmedetomidine (Precedex®)
• MOA: selective α2-agonist sedative, small
analgesic properties
• Patients remain sedated when undisturbed, but
arouse readily---does not work well as
monotherapy for sedation
• Indication
– Short-term sedation of mechanically ventilated
patients with anticipated early extubation
– ISMC ICU use restricted for 24 h for extubation
41

Dexmedetomidine (Precedex®)
• ADRs: hypotension (24-56%), hypertension with bolus
doses, bradycardia (5-42%), can be severe
• Caution with vasodilators or drugs that ↓ HR
• Expensive: 3x propofol
Concentration

200 mcg/50 mL

Starting rate

0.2 mcg/kg/hr
Optional loading dose: 1 mcg/kg over 10 min (omit if
concern for hemodynamic compromise)

Titration

0.1 mcg/kg/hr every 15 minutes to RASS of 0 to -2. Allow
15 minutes for peak effect after each dosage change.
Abrupt discontinuation should be avoided (nervousness,
agitation, HA, rapid ↑ BP).

Maintenance

0.2-1.4 mcg/kg/hr
42
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NEUROMUSCULAR
BLOCKERS
Cisatracurium
Succinylcholine
Rocuronium
43

NMBAs
• NMBAs have NO analgesic or amnestic effects
• Patients may appear comfortable, but analgesia and
sedation MUST BE USED
• Indications
– All other modalities must be tried first- NMBAs should be a last resort
– Facilitate mechanical ventilation: used for both rapid sequence
intubation (RSI) and ventilator asynchrony
– Acute respiratory distress syndrome (ARDS)
– Therapeutic hypothermia after cardiac arrest

44
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NMBA Monitoring
• Sedation: BIS monitor (keep BIS 40-60)
Sedation Level

BIS value
0

Level of Consciousness
Flat line EEG, absence of brain activity

Deep Sedation

20-40

Burst suppression

Deep Sedation

40-60

Low probability of explicit recall Unresponsive
to verbal stimulus

Moderate
Sedation

60-80

Responds to loud commands or mild
prodding/shaking

Anxiolysis

80-90

Responds to normal voice

Anxiolysis

90-100

Awake

• Paralysis: Peripheral Nerve Stimulator (2:4)
No. of twitches

Approximate %
receptors blocked

0
1
2
3
4

100
90
75-80
75
0

45

NMBA Checklist
Before starting a NMBA make sure:
Scheduled or continuous analgesia
Scheduled or continuous sedation
DVT prophylaxis
Stress ulcer prophylaxis
Eye drops or ointment
Not receiving corticosteroids
(prolonged paralysis)
46
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Cisatracurium (Nimbex®)
• Most common paralytic infusion at ISMC
• Metabolism not affected by renal or
hepatic disease

Concentration

200 mg/100 mL

Starting rate

0.5 mcg/kg/min

Titration

Titrate by 1 mcg/kg/min every 10 minutes to goal
train-of-four of 2:4

Max rate

10 mcg/kg/min
47

Rapid Sequence Intubation (RSI)
– Definition: using a sedative (often etomidate) along with a NMBA
to quickly achieve readiness for endotracheal intubation
– Associated with an improvement in intubating conditions and
reduction in hypoxemia and complications (aspiration, traumatic
intubation, dental injury)
•

Succinylcholine:
– 1-1.5 mg/kg once (~100 mg in a 70 kg adult)
– Avoid when depolarizing effect can cause increase in extracellular potassium
(sustained muscle weakness, prolonged immobility, renal failure)

•

Rocuronium:
– 1-1.2 mg/kg once
– Used in RSI when succinylcholine is contraindicated
– Duration much longer than succinylcholine (60-80 min); may not be
appropriate for difficult intubations or mask ventilation as hypoxemia can
occur
48
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Application
• LT continues to decline and develops
respiratory failure and ARDS as a
complication of HCAP/sepsis. His SCr is
3.4. The pulmonologist wants to start a
paralytic.
• Which paralytic would you recommend
and what other recommendations would
you make?
49

ANTIARRHYTHMICS
Diltiazem
Amiodarone
Esmolol

50
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Diltiazem (Cardizem®)
• MOA: non-dihydropyridine CCB
• Indications:
– Lower the ventricular response in A-fib, Atrial flutter, and SVT

• WATCH for:
– Bradycardia
– Hypotension
Concentration 125 mg/125 mL
Bolus dose

Starting dose
Titration
Max Rate

A bolus dose of 0.25 mg/kg (in adults usually 10-20 mg) may be
given over 2 minutes. May be repeated once at 0.35 mg/kg after
15 minutes.
5-10 mg/hr
Titrate by 5 mg/hr every 15 minutes up to 15 mg/hr
15 mg/hr
51

Amiodarone
•
•

MOA: class III antiarrhythmic agent that slows intra-cardiac conduction.
Indication:
– Ventricular arrhythmias (VT, Vfib)
– Rapid ventricular rates associated with SVT, Afib
– Conversion from atrial fibrillation RVR (particularly if little response to BB or
CCB)

•
•
•
•

0.22 micron filter required
Infuse through dedicated IV line (central preferred)
Contraindication: 2nd or 3rd degree AV heart block, bradycardia, cardiogenic
shock
WATCH for: bradycardia and hypotension, QT prolongation
Usual Concentration

Rate (mg/min)

Rate (mL/hr)

Loading Dose

150 mg/ 100 mL D5W 15 mg/min

600 mL/hr for 10
minutes

Slow Loading Dose

450 mg/250 mL D5W

1 mg/min

33.3 mL/hr for 6 hours

Maintenance Dose

450 mg/250 mL D5W

0.5 mg/min

16.7 mL/hr for 18
hours

52

26

Esmolol (Brevibloc®)
• MOA: short acting β1-selective beta-blocker
• Indication: SVT, HTN, atrial fibrillation/flutter
• Contraindication: HF, cardiogenic shock, bradycardia,
2nd or 3rd degree heart block, hypotension
• WATCH for: bradycardia and hypotension
Concentration 2500 mg/250 mL (DS 2000 mg/100 mL)
Bolus dose

500 mcg/kg loading dose over 1 minute. Loading dose may be
repeated up to three times per physician order.

Starting dose

50 mcg/kg/min

Titration

Titrate by 50 mcg/kg/min every 4 minutes to patient response

Weaning

Decrease the infusion rate in increments to 25 mcg/kg/min after
therapeutic dose has been reached

Max Rate

200 mcg/kg/min

53

Application
• LT is improving due to his excellent care
and is able to come off all his IV drips
except for norepinephrine. You notice that
his HR is 128 with irregularly irregular R-R
and no p waves.
• What recommendations would you make?

54
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ANTIHYPERTENSIVES
Nicardipine
Nitroprusside
Nitroglycerin

55

Nicardipine (Cardene®)
•
•
•
•
•

MOA: dihydropyridine calcium channel blocker
Indication: antihypertensive, HTN crisis, ischemic stroke
Contraindication: aortic stenosis (may ↓ coronary perfusion → ischemia)
Peripheral or central line
WATCH for: hypotension, reflex tachycardia, headache, peripheral
edema
Concentration

50 mg/250 mL

Starting dose

5 mg/hr

Titration

Titrate by 2.5 mg/hr every 15 minutes to patient response.
Do not abruptly discontinue. Abrupt withdrawal may cause rebound
angina in patients with CAD.

Max Rate

15 mg/hr
56
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Nitroprusside (Nipride®)
•
•
•

MOA: direct vasodilator potent arterial vasodilator
Indications: usually LAST OPTION for hypertensive crisis, ischemic stroke, HF, post-CABG
Cyanide toxicity at high infusion rates for long periods of time. Use with caution in hepatic
or renal impairment
Light sensitive: keep drug and tubing covered
WATCH for:

•
•

–

Excessive hypotension: do not leave the bedside while titrating. Sudden and extreme decreases
in systolic blood pressure have been associated with this infusion. Monitor BP every 5 minutes
during titration.
Cyanide toxicity: monitor for cyanide toxicity via metabolic acidosis and SVO2

–

•
•

–
–

Initial symptoms: flushing, tachycardia, tachypnea, headache, and dizziness.
Worsening toxicity: loss of consciousness, coma, hemodynamic compromise, arrhythmias, seizures, apnea,
cardiac arrest, and death.

Thiocyanate toxicity: in renal impairment, prolonged infusion (>3 days), dose ≥4 mcg/kg/ minute
Headache, Nausea

Concentration

50 mg/250 mL . May be mixed in the ICU in an emergency

Starting dose

0.3 mcg/kg/min

Titration

Increase by 0.5 mcg/kg/min every 3-5 minutes to effect or until headache/nausea occurs

Max Rate

10 mcg/kg/min (rarely need greater than 4 mcg/kg/min).
When administered by prolonged infusion faster than 2 mcg/kg/minute, cyanide is generated
57
faster than an unaided patient can handle.

Nitroglycerin
•
•
•

MOA: coronary vasodilator and peripheral venodilator (reduces
preload)
Indication: angina, hypertension, CHF, and pulmonary hypertension
Contraindications:
– Head trauma or ICH
– Within 24 hours of sildenafil (Viagra®) or vardenafil (Levitra®) or within 48 hours
of tadalafil (Cialis®). May cause severe hypotension, MI, or death

•

WATCH for:
–
–
–
–

Hypotension
Lightheadedness, headache (common)
Tachycardia
Flushing of the face and neck

Concentration

Premix 50 mg/250 mL

Starting dose

5 mcg/min IV

Titration

Increase by 5 mcg/min every 3-5 minutes to 20 mcg/min. If no response at 20 mcg/min,
increase by 10 mcg/min every 3-5 minutes.

Max Rate

200 mcg/min
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Application
• Two weeks later LT was discharged to
LTAC, but he returns to the ER after one
week with crushing chest pain and BP
240/172. The plan is to go to the cath lab.
• In the meantime, what is your
recommendation for his BP?
• What are your HTN recommendations
after placement of 2 stents?
59

ANTITHROMBOTICS
Heparin
Bivalirudin
Eptifibatide
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HEPARIN PROTOCOL
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Heparin
• MOA: Potentiates antithrombin III and inactivates thrombin
• Indication: anticoagulant for DVT/PE or in ACS
• Monitor: HPTT 6 hours after initiation and each rate
change (keep 42-70), S/S bleeding, H/H
• Antidote: protamine sulfate

Concentration
Loading Dose
Maintenance
dose

DVT/PE
Premix 25,000 units/500 mL
80 units/kg (round to nearest 100
units), max 10,000 units
18 units/kg/hr

ACS

(round to nearest 50 units), not to
exceed 1500 units/hr

(round to nearest 50 units), max
1000 units/hr

60 units/kg, round to nearest
100 units, max 4000 units
12 units/kg/hr

Titration

Per protocol

Max Rate

Per protocol (sliding scale calculates for maximum weight in kg)62
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Loading Dose
DVT/PE

ACS

63

Initial Rate
DVT/PE

ACS

64
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Titration
•
•

Pharmacist calculates and enters patient specific doses in order comments
Bolus dose and rates vary based on HPTT, patient weight, and protocol (VTE vs. ACS)
Heparin for VTE: titration for 70 kg patient
HPTT < 32
HPTT 32 - <35
HPTT 35 - 40
HPTT 40 - 41
HPTT 42 - 70
.
HPTT 71 - 75
HPTT 76 - 85
HPTT 86 - 90
HPTT 91 - 110
HPTT > 110

5600 unit bolus and INCrease infusion BY 300 units/hour
4200 unit bolus and INCrease infusion BY 200 units/hour
2800 unit bolus and INCrease infusion BY 150 units/hour
NO bolus; INCrease infusion BY 50 units/hour
NO CHANGE; Recheck HPTT in 6 hrs. After two that result in no
rate change, order HPTT next morning
NO bolus; DECrease infusion BY 50 units/hour
NO bolus; DECrease infusion BY 100 units/hour
NO bolus; DECrease infusion BY 150 units/hour
HOLD INF x 1 hr, then resume at rate lower BY 200 units/hour
HOLD INF and notify physician promptly

Heparin for ACS: titration for 70 kg patient
HPTT < 32
HPTT 32 - <35
HPTT 35 - 41
HPTT 42 - 70
.
HPTT 71 - 78
HPTT 79 - 85
HPTT 86 - 90
HPTT 91 - 110
HPTT 111 - 155
HPTT > 155

4000 unit bolus and INCrease infusion BY 200 units/hour
3500 unit bolus and INCrease infusion BY 150 units/hour
2800 unit bolus and INCrease infusion BY 100 units/hour
NO CHANGE; Recheck HPTT in 6 hrs. After two that result in no
rate change, order HPTT next morning
NO bolus; DECrease infusion BY 50 units/hour
NO bolus; DECrease infusion BY 100 units/hour
NO bolus; DECrease infusion BY 100 units/hour
HOLD INF x 1 hr, then resume at rate lower BY 200 units/hour
HOLD INF x 90 min, then resume at a rate lower BY 200 units/hour
HOLD INF x 90 min, then resume at a rate lower BY 300 units/hour
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Titration
Scroll over heparin order to see
titration rates
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Laboratory Monitoring
What is HPTT?
Stat labs
Daily labs
Nurse ordered HPTT per protocol

Please make sure to check labs q 6 hours until you reach NO Change X 2
then you may change to q day HPTT
67

HPTT Labels
• If more than one HPTT is ordered at a
time, ensure that the time on the label
matches the time the level was drawn.
– Levels have been reported at the wrong time
due to label mismatch.
– This can cause patient harm by leading to
incorrect dose adjustments.
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Rate Documentation
How to document rate changes on the MAR
•
•
•

Go to heparin order (Modify heparin order)
Change unit rate to desired units per hour per protocol
Pharmacy will change the rate on the MAR
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Rate Documentation
• Modify unit rate to desired units per hour
per protocol

70
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Rate Documentation
• Document as rate change in the MAR
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Holding Infusion due to HPTT
• If HPTT 91 – 110, the order states to “HOLD INFUSION x 1 hr, then resume at
a rate lower BY 200 units/hour”
• Document as rate change to zero and add comment about holding dose x 1 hr
• After holding for one hour, document rate change with new infusion rate.
Modify the heparin order with the new rate.

72
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Bolus Documentation
How to document bolus on the MAR
•

Bolus dose is located in the PRN orders on the MAR

•

Scan your heparin and document units given per protocol.
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Heparin Titration Problem
• WZ is on a heparin drip at 1300 units/hr. The 24 hour
HPTT is 33. What should you do?
HPTT < 32
HPTT 32 - <35
HPTT 35 - 40
HPTT 40 - 41
HPTT 42 - 70
.
HPTT 71 - 75
HPTT 76 - 85
HPTT 86 - 90
HPTT 91 - 110
HPTT > 110

5600 unit bolus and INCrease infusion BY 300 units/hour
4200 unit bolus and INCrease infusion BY 200 units/hour
2800 unit bolus and INCrease infusion BY 150 units/hour
NO bolus; INCrease infusion BY 50 units/hour
NO CHANGE; Recheck HPTT in 6 hrs. After two that result in no
rate change, order HPTT next morning.
NO bolus; DECrease infusion BY 50 units/hour
NO bolus; DECrease infusion BY 100 units/hour
NO bolus; DECrease infusion BY 150 units/hour
HOLD INF x 1 hr, then resume at rate lower BY 200 units/hour
HOLD INF and notify physician promptly

• Bolus 4200 units, document in MAR
• Modify order per protocol and increase infusion to 1500
units/hr.
74
• Order HPTT 6h after rate change.
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Heparin Titration Problem
• HPTT rechecked after 6 hours is 45. The current rate is
1500 units/hr. What should you do?
HPTT < 32
HPTT 32 - <35
HPTT 35 - 40
HPTT 40 - 41
HPTT 42 - 70
.
HPTT 71 - 75
HPTT 76 - 85
HPTT 86 - 90
HPTT 91 - 110
HPTT > 110

5600 unit bolus and INCrease infusion BY 300 units/hour
4200 unit bolus and INCrease infusion BY 200 units/hour
2800 unit bolus and INCrease infusion BY 150 units/hour
NO bolus; INCrease infusion BY 50 units/hour
NO CHANGE; Recheck HPTT in 6 hrs. After two that result in no
rate change, order HPTT next morning.
NO bolus; DECrease infusion BY 50 units/hour
NO bolus; DECrease infusion BY 100 units/hour
NO bolus; DECrease infusion BY 150 units/hour
HOLD INF x 1 hr, then resume at rate lower BY 200 units/hour
HOLD INF and notify physician promptly

• No change in rate
• Order new 6 hr HPTT. If level is 42-70, NO CHANGE
required and confirm AM HPTT has been ordered.
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ANTITHROMBOTICS
Heparin
Bivalirudin
Eptifibatide
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Bivalirudin (Angiomax®)
• MOA: direct thrombin inhibitor
• Indication: anticoagulant for ACS, HIT
• Target aPTT 42-70 seconds, check 2 hours after
initiation and every 4 hours until in range x 2
consecutively
PCI

HIT

Concentration 250 mg/500 mL

Titration

0.75 mg/kg x 1 prior to PCI
1.75 mg/kg/hr during procedure and 4
hours after procedure
May be continued up to 10 hours after
procedure at 0.2 mg/kg/hr
Not titrated or per orders

Max Rate

1.75 mg/kg/hr

Bolus
Starting dose

None
CrCl > 60 mL/min: 0.15 mg/kg/hr
CrCl 30-60 mL/min: 0.08 mg/kg/hr
CrCl < 30 mL/min: 0.04 mg/kg/hr
CRRT: 0.03-0.07 mg/kg/hr
Per protocol
0.3 mg/kg/hr without checking for
coagulation abnormalities
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Eptifibatide (Integrilin®)
•
•
•
•
•
•

MOA: GP 2b3a inhibitor
Indication: antiplatelet for ACS or PCI
Contraindicated: SCr > 4 or on dialysis (don’t use CrCl in computer
b/c have to use ABW)
Before PCI, concomitant heparin or enoxaparin recommended (not
usually after)
DO give with aspirin and a P2Y12 (clopidogrel, prasugrel)
WATCH for: S/S bleeding, platelet count
Concentration

Premix 75 mg/100 mL

Bolus dose

180 mcg/kg, not adjusted based on renal function (max 22.6 mg) over 1-2 minutes

Starting dose

CrCl > 50 mL/min: 2 mcg/kg/min
CrCl <= 50 mL/min or SCr 2-4: 1 mcg/kg/min
Not titrated. Continue until discharge, CABG, or up to 72 hours (total infusion time
<96 hours)
CrCl > 50 mL/min: 15 mg/hr
78
CrCl <= 50 mL/min or SCr 2-4: 7.5 mg/hr

Titration
Max Rate
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Application
• After receiving the two stents, LT is
admitted to the ICU.
• Which antithrombotic may he still be
receiving?
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Calculation Practice
• You want to start a norepinephrine drip on
a 60 kg female at 0.2 mcg/kg/min using
the standard concentration (4 mg/250 mL).
• How many mcg/min is that?
• How many mL/hr is that?

80
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Calculation Answers
Calculate mcg/min

0.2 mcg x 60 kg = 12 mcg
kg
min
Calculate mL/hr

12 mcg x _1 mg__= 0.012 mg
min 1000 mcg
min
0.012 mg x 60 min x 250 mL = 45 mL
min
hour
4 mg
hour
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For More Information
Person

Number

Critical Care Pharmacy Specialist: Cheri Walker

1-1398

Infectious Diseases Pharmacy Specialist: Ann Nguyen

6-7258

Cardiology Pharmacy Specialist: Kristin Montarella

1-1331

ICU mobile pharmacist

1-1401

Central pharmacy

6-7255

IV room

6-7261
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